Epigral reported Q1 FY27 revenue up 15% YoY to INR 709 Cr and PAT up 25% to INR 99 Cr, despite a challenging quarter.

The company announced a strategic INR 600 Cr capex for Epoxy Resin & Formulations (125,000 TPA) and a Multipurpose Plant for downstream ECH/chlorotoluenes derivatives.

This forward integration leverages in-house raw materials, with a pilot plant operational by Q2 FY27. Management aims for 15-20% CAGR growth and 20% ROCE, targeting INR 1,300-1,500 Cr additional peak revenue from new projects.

Diversification and integrated manufacturing drive a confident long-term outlook.